Future developments: measurable residual disease

Research output: Chapter in Book/Report/Conference proceedingChapter

Standard

Future developments : measurable residual disease. / Venditti, Adriano; Valk, Peter ; Russell, Nigel H; Freeman, Sylvie.

Acute Myeloid Leukemia. ed. / Christoph Röllig; Gert J. Ossenkoppele. 1. ed. Springer, 2021. p. 317-337 (Hematologic Malignancies (HEMATOLOGIC)).

Research output: Chapter in Book/Report/Conference proceedingChapter

Harvard

Venditti, A, Valk, P, Russell, NH & Freeman, S 2021, Future developments: measurable residual disease. in C Röllig & GJ Ossenkoppele (eds), Acute Myeloid Leukemia. 1 edn, Hematologic Malignancies (HEMATOLOGIC), Springer, pp. 317-337. https://doi.org/10.1007/978-3-030-72676-8_18

APA

Venditti, A., Valk, P., Russell, N. H., & Freeman, S. (2021). Future developments: measurable residual disease. In C. Röllig, & G. J. Ossenkoppele (Eds.), Acute Myeloid Leukemia (1 ed., pp. 317-337). (Hematologic Malignancies (HEMATOLOGIC)). Springer. https://doi.org/10.1007/978-3-030-72676-8_18

Vancouver

Venditti A, Valk P, Russell NH, Freeman S. Future developments: measurable residual disease. In Röllig C, Ossenkoppele GJ, editors, Acute Myeloid Leukemia. 1 ed. Springer. 2021. p. 317-337. (Hematologic Malignancies (HEMATOLOGIC)). https://doi.org/10.1007/978-3-030-72676-8_18

Author

Venditti, Adriano ; Valk, Peter ; Russell, Nigel H ; Freeman, Sylvie. / Future developments : measurable residual disease. Acute Myeloid Leukemia. editor / Christoph Röllig ; Gert J. Ossenkoppele. 1. ed. Springer, 2021. pp. 317-337 (Hematologic Malignancies (HEMATOLOGIC)).

Bibtex

@inbook{3d7a2cd6662f4412afd1e5f69c2f3076,
title = "Future developments: measurable residual disease",
abstract = "Measurable (previously minimal) residual disease (MRD) detection in acute myeloid leukemia (AML) has progressed beyond being a recognized strong prognostic factor. MRD-risk stratification is now incorporated into many treatment schedules and there is ongoing evaluation of MRD-directed therapy. Evolving assay technology such as next-generation sequencing has resulted in an increased repertoire of potential molecular biomarkers for MRD but molecular MRD can be challenging in AML, particularly in older adults, due to the oligoclonal profile of leukemic and co-existing pre-leukemic progenitors. Evaluation of different MRD markers/assays has also extended to assessing the therapeutic efficacy of novel drugs. How MRD assessments pre- and post-transplant should guide the delivery of allogeneic transplant and peri-transplant interventions to reduce relapse remains a key question but recent studies contribute important additional information. This review will update on what has been happening in these different areas and consider prospects for the future use and interpretation of MRD in the setting of trials and routine clinical practice.",
keywords = "AML, MRD, Risk-stratification, NGS, Flow cytometry, Transplant, NPM1, RT-qPCR, IDH, FLT3",
author = "Adriano Venditti and Peter Valk and Russell, {Nigel H} and Sylvie Freeman",
year = "2021",
month = may,
doi = "10.1007/978-3-030-72676-8_18",
language = "English",
isbn = "9783030726751",
series = "Hematologic Malignancies (HEMATOLOGIC)",
publisher = "Springer",
pages = "317--337",
editor = "R{\"o}llig, {Christoph } and Ossenkoppele, {Gert J. }",
booktitle = "Acute Myeloid Leukemia",
edition = "1",

}

RIS

TY - CHAP

T1 - Future developments

T2 - measurable residual disease

AU - Venditti, Adriano

AU - Valk, Peter

AU - Russell, Nigel H

AU - Freeman, Sylvie

PY - 2021/5

Y1 - 2021/5

N2 - Measurable (previously minimal) residual disease (MRD) detection in acute myeloid leukemia (AML) has progressed beyond being a recognized strong prognostic factor. MRD-risk stratification is now incorporated into many treatment schedules and there is ongoing evaluation of MRD-directed therapy. Evolving assay technology such as next-generation sequencing has resulted in an increased repertoire of potential molecular biomarkers for MRD but molecular MRD can be challenging in AML, particularly in older adults, due to the oligoclonal profile of leukemic and co-existing pre-leukemic progenitors. Evaluation of different MRD markers/assays has also extended to assessing the therapeutic efficacy of novel drugs. How MRD assessments pre- and post-transplant should guide the delivery of allogeneic transplant and peri-transplant interventions to reduce relapse remains a key question but recent studies contribute important additional information. This review will update on what has been happening in these different areas and consider prospects for the future use and interpretation of MRD in the setting of trials and routine clinical practice.

AB - Measurable (previously minimal) residual disease (MRD) detection in acute myeloid leukemia (AML) has progressed beyond being a recognized strong prognostic factor. MRD-risk stratification is now incorporated into many treatment schedules and there is ongoing evaluation of MRD-directed therapy. Evolving assay technology such as next-generation sequencing has resulted in an increased repertoire of potential molecular biomarkers for MRD but molecular MRD can be challenging in AML, particularly in older adults, due to the oligoclonal profile of leukemic and co-existing pre-leukemic progenitors. Evaluation of different MRD markers/assays has also extended to assessing the therapeutic efficacy of novel drugs. How MRD assessments pre- and post-transplant should guide the delivery of allogeneic transplant and peri-transplant interventions to reduce relapse remains a key question but recent studies contribute important additional information. This review will update on what has been happening in these different areas and consider prospects for the future use and interpretation of MRD in the setting of trials and routine clinical practice.

KW - AML

KW - MRD

KW - Risk-stratification

KW - NGS

KW - Flow cytometry

KW - Transplant

KW - NPM1

KW - RT-qPCR

KW - IDH

KW - FLT3

UR - https://www.springer.com/gb/book/9783030726751

U2 - 10.1007/978-3-030-72676-8_18

DO - 10.1007/978-3-030-72676-8_18

M3 - Chapter

SN - 9783030726751

T3 - Hematologic Malignancies (HEMATOLOGIC)

SP - 317

EP - 337

BT - Acute Myeloid Leukemia

A2 - Röllig, Christoph

A2 - Ossenkoppele, Gert J.

PB - Springer

ER -